The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB # 21-001603; 2) study the efficacy of brivaracetam to suppress epileptic activity and pathological high frequency oscilations (pHFOs) during hippocampal depth electrode and scalp EEG in patients with MCI and AD; and 3) investigate the effects of brivaracetam on cognition in an open-label pilot study.

开始日期2025-01-01

申办/合作机构

University of California, Los Angeles

100 项与布立西坦相关的临床结果

登录后查看更多信息

100 项与布立西坦相关的转化医学

登录后查看更多信息

100 项与布立西坦相关的专利（医药）

登录后查看更多信息

727

项与布立西坦相关的文献（医药）

2025-12-01·Acta Epileptologica

Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database

Article

作者: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan

Abstract:

Background:

Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods:

This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).

Results:

A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.

Conclusions:

This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.

2025-12-01·EPILEPSY & BEHAVIOR

Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States

Article

作者: Sperling, Michael R ; Henninger, Heidi ; Elmoufti, Sami ; Martin, Melinda S ; Dave, Hina ; Gelfand, Michael ; Porter, Roger J ; Schulz, Anne-Liv ; French, Jacqueline A ; Altalib, Hamada Hamid ; Dongre, Prashant

OBJECTIVE:

Evaluate real-world effectiveness, patient-reported outcomes (PROs), and safety/tolerability of brivaracetam in patients (≥16 years) with focal-onset seizures currently receiving ≥ 1 antiseizure medication (ASM), and with historical or current use of levetiracetam, lamotrigine, oxcarbazepine, and/or carbamazepine.

METHODS:

EP0088 was a 12-month, prospective, observational study of brivaracetam in a clinical practice setting in the US. Primary study outcome was brivaracetam retention at 12 months after brivaracetam initiation. Effect of brivaracetam on patients' perceptions of their health was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) short forms and Seizure-Related Disability Assessment Scale (SERDAS). Safety outcomes included incidence of treatment-emergent adverse events (TEAEs).

RESULTS:

254 patients (mean age: 44.3 years; median duration of epilepsy: 17.3 years) received ≥ 1 brivaracetam dose (Safety Set; SS). Patients had a median of 3.0 historical and 2.0 concomitant ASMs (SS). For all patients (SS), including those who dropped out with unknown brivaracetam treatment status, 12-month brivaracetam retention was 57.1 % (n = 145/254); in patients with known brivaracetam treatment status (post hoc analysis), 12-month brivaracetam retention was 72.1 % (n = 145/201). Slight improvements in mean PROMIS T-scores, and improvements in mean SERDAS scores, were seen by month 1.5, and generally maintained up to 12 months (Full Analysis Set). 49.6 % of patients reported ≥ 1 TEAE, 38.2 % had drug-related TEAEs, and 16.1 % discontinued due to TEAEs (SS).

CONCLUSIONS:

Brivaracetam was effective in patients with difficult-to-control focal-onset seizures; as shown by brivaracetam retention at 12 months. Improvements in PROs were seen early. Brivaracetam was well-tolerated and no new safety signals were observed.

2025-11-01·EPILEPSY & BEHAVIOR

Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population

Article

作者: Jimenez, Anthony D ; Gopaul, Margaret ; Orner, Michelle ; DeBonis, Danny ; Nuthalapati, Poojith ; Altalib, Hamada H ; Okafor, Chinenye M

INTRODUCTION:

Epilepsy is a chronic neurological disorder, affecting approximately 50 million people worldwide. There is limited data on the use of newer anti-seizure medicines (ASMs) and their cognitive and psychiatric adverse effects (AEs), despite increasing use. We aimed to describe the AE profile of newer ASMs in the real-world veteran population with Epilepsy comparing those who develop cognitive or psychiatric AEs to those who did not.

METHODS:

A retrospective analysis of veterans (n = 2636) diagnosed with epilepsy via ICD-10 codes was conducted in collaboration with the Veterans Affairs (VA) Office Quality and Patient Safety Analytics and Performance Integration program. Neurology notes of veterans diagnosed with epilepsy, between January 2011 and June 2022 across the VA system were sampled to evaluate cognitive and psychiatric AEs. For this index study, only patients who were prescribed any of the five newer anti-seizure medications (brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel) were included. Selection of these ASMs were made a priori as these were the most recently approved ASMs for use in the VA.

RESULTS:

Among the 2636 Veterans that were included in the index study, median age (Q1-Q3) was 64 (50-73) years with 88.1 % male participants, a population known to have higher prevalence of psychiatric and cognitive disorders. Overall, 70.7 % White Veterans, and 6.5 % Hispanic. 86.8 % were prescribed lacosamide while only 4.1 %, 4.3 %, 4.4 %, and 4.8 % were prescribed perampanel, clobazam, brivaracetam, and eslicarbazepine respectively. Overall, 63 (2.4 %) and 39 (1.5 %) Veterans reported cognitive and psychiatric AEs, respectively. Veterans with epilepsy were more likely to experience cognitive AEs if they were independently older (p = 0.004) and on Perampanel (OR 2.58, p = 0.03). Similarly, psychiatric AEs were more likely among those on Perampanel (OR 4.49), whereas they were less frequent in those taking frequent lacosamide (OR 0.38). Cognitive or psychiatric AEs often lead to treatment discontinuation in this population.

CONCLUSION:

In a population of veterans with epilepsy, clinicians should exercise caution in monitoring for cognitive and psychiatric adverse effects prescribed with the newer ASMs. Further research could help elucidate the dosage and delay at which these side effects would occur after treatment initiation.

109

项与布立西坦相关的新闻（医药）

2025-07-10

·米内网

【火热】青峰医药入局8亿潜力品种

精彩内容近日，青峰医药的富马酸伏诺拉生片以仿制4类报产获受理。这是一款钾离子竞争性酸阻滞剂，原研产品2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过8亿元。今年以来，青峰医药有7个仿制药、1款1类新药首次报产/报临床。富马酸伏诺拉生片是由武田药品开发的一款钾离子竞争性酸阻滞剂(P-CAB)，用于治疗反流性食管炎，也可与适当的抗生素联用以根除幽门螺杆菌。米内网数据显示，富马酸伏诺拉生片已被纳入国家医保乙类目录，原研产品近年来在中国三大终端六大市场的销售额均以两位数的增速持续增长，2024年突破8亿元，2025年第一季度以35%的增速继续增长。近年来中国三大终端六大市场富马酸伏诺拉生片销售情况（单位：万元）来源：米内网格局数据库在近日流出的第十一批国采拟采购药品清单征求意见稿中，富马酸伏诺拉生片赫然在列。该药已有21家药企视同过评，包括石药集团、正大制药、石家庄四药、康弘药业、齐鲁制药、人福医药、科伦药业、扬子江药业、鲁南制药等。此外，70余家药企的产品以新分类报产在审，竞争激烈。米内网数据显示，今年以来，青峰医药有7个品种以新注册分类报产，包括3款消化系统及代谢药、2款抗肿瘤和免疫调节剂及2款神经系统药物，其中阿贝西利片、布立西坦注射液、利那洛肽胶囊、布立西坦口服溶液均暂无首仿（含剂型首仿）获批。今年以来青峰医药报产的仿制药来源：米内网中国申报进度（MED）数据库此外，青峰医药还有1款1类新药KR230109乳膏于今年1月提交IND，并于3月获得临床试验默示许可，4月开始启动I期临床，适用于寻常型痤疮患者的局部治疗，可谓进展神速。资料来源：米内网数据库、CDE官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至7月10日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

带量采购

2025-06-18

·米内网

科伦药业厉害了！拿下35个重磅品种，26款1类新药、74个新品出击，198个过评品种霸屏

精彩内容近段时间，科伦药业产品管线进展频频：1类新药注射用SKB315新适应症获批临床、注射用头孢唑林钠/氯化钠注射液国内第2家获批等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，2024年研发投入21.71亿元（+11.2%），目前有42款新药（26款1类新药）处于申报临床及以上阶段；仿制药方面，累计有198个品种过评（50余个首家/独家），74个新品瞄准160亿市场。拿下35个品种！198个过评品种霸屏近日，科伦药业2款3类仿制药获批生产并视同过评，为注射用头孢唑林钠/氯化钠注射液、注射用青霉素钠，均属于全身用抗感染药物。其中，注射用头孢唑林钠/氯化钠注射液国内第2家获批，同时也是公司粉液双室袋平台第11个获批的产品。今年以来，科伦药业（含子公司及联营公司，下同）产品管线持续推进。在新注册分类品种审评方面，科伦药业有35个品种获批生产并视同过评，领跑国内其他药企。2025年以来科伦药业获批上市的仿制药来源：米内网中国申报进度（MED）数据库35个品种中，有多个品种为国内首批上市，其中芦曲泊帕片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液等为国内首仿+首家过评，阿帕他胺片、枸橼酸钠血滤置换液、注射用头孢他啶/氯化钠注射液等为国产第2家获批，复方氨基酸注射液(18AA-Ⅸ)、他克莫司缓释胶囊、昂丹司琼口溶膜、复方电解质醋酸钠注射液等为国产第3家获批等。截至目前，科伦药业已有198个品种通过/视同通过一致性评价，在过评品种数TOP10集团中排位第二。其中，50余个品种为国内首家过评，包括芦曲泊帕片、氢溴酸替格列汀片、琥珀酸曲格列汀片、泊沙康唑口服混悬液、注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等18个独家过评品种。在国家开展的九批十轮化药集采中，科伦药业分别有1个、5个、4个、4个、11个、11个、7个、4个、12个品种成功中选，合计59个品种。集采常态化推进背景下，科伦药业恰逢产品线密集收获期，并积极参与集采，目前已成为集采头部供应商之一。在第十一批集采中，预计科伦药业将仍旧为“主力军”，目前已有近40个品种达到入围门槛，注射剂占“半壁江山”。其中，有10余个为2025年后新获批品种，包括罗沙司他胶囊、注射用头孢他啶阿维巴坦钠(4:1)等临床畅销品种。26款1类新药出击，猛攻2300亿市场今年以来，科伦药业国内新药研发进展不断：生物类似药西妥昔单抗注射液获批上市，为国产首家；PD-L1单抗塔戈利单抗注射液、TROP2 ADC注射用芦康沙妥珠单抗获批新适应症；1类新药注射用SKB445、SKB107注射液，以及2.2类改良型新药KLA480注射液、注射用KLA578-1、KLA514-2片、A140注射液等均首次获批临床。国际化方面，新型ADC药物SKB518在美获批临床，用于治疗晚期实体瘤，该药已在国内开展II期临床试验；以不超过9.7亿美元的首付款和里程碑付款，将TSLP单抗SKB378/HBM93781在全球范围内（不包括大中华区以及部分东南亚及西亚国家）的研发、生产和商业化的独家授权给Windward Bio等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，不断加大研发投入支持创新发展。2023年公司研发投入19.5亿元，同比增长7.59%；2024年进一步增长至21.71亿元，同比增长11.2%。近年来科伦药业研发投入情况（单位：亿元）来源：公司公告，米内网整理目前科伦药业有42款新药在国内处于申报临床及以上阶段，涉及26款1类新药、15款2类改良型新药、1款生物类似药，聚焦肿瘤、精神神经、心血管、肝病、呼吸等疾病领域，其中抗肿瘤药独占“半壁江山”。米内网数据显示，2024年中国三大终端六大市场抗肿瘤和免疫调节剂（化学药+生物药）销售额超过2300亿元。科伦药业国内在研新药来源：米内网综合数据库42款新药中，1类新药注射用博度曲妥珠单抗、制剂改良型新药布瑞哌唑口溶膜已申报NDA，上市可期。博度曲妥珠单抗为靶向HER2的ADC药物，全球已获批上市的同靶点同类型药物中，罗氏的恩美曲妥珠单抗、第一药品/阿斯利康的德曲妥珠单抗2024年全球销售额分别达19.98亿瑞士法郎、5.45亿美元。口溶膜制剂方面，昂丹司琼口溶膜已顺利获批，布瑞哌唑口溶膜、枸橼酸西地那非口溶膜2款产品报产在审，盐酸达泊西汀口溶膜、盐酸鲁拉西酮口溶膜等获批临床，提升了公司复杂制剂领域产线价值。在研1类新药中，ADC药物是科伦药业重点布局的药物形式之一，目前已有芦康沙妥珠单抗（TROP2 ADC）1款新药获批上市，此外还有9款ADC药物处于获批临床及以上阶段，其中新型双抗ADC药物SKB571，以及SKB518、MK-6204、SKB445等具有潜在FIC靶点的新型ADC药物等均处于I期临床。目前全球已有10多款ADC药物获批上市，2024年全球销售额合计约130亿美元。74个新品瞄准160亿市场！29个品种抢首仿仿制药申报方面，目前科伦药业还有74个新注册分类品种在审（不含已有批文、主动撤回品种），形成了梯度丰富的研发管线，主要集中在血液和造血系统药物（16个）、神经系统药物（15个）、全身用抗感染药物（8个）、消化系统及代谢药（7个）等。74个品种2024年在中国三大终端六大市场的销售额合计超过160亿元。其中，低钙腹膜透析液(乳酸盐-G1.5%)、艾拉莫德片均超过10亿元，低钙腹膜透析液(乳酸盐-G2.5%)、丙戊酸钠缓释片(Ⅰ)均超过9亿元，双氯芬酸二乙胺乳胶剂、磷酸芦可替尼片均超过8亿元。29个品种暂无首仿（含剂型首仿）获批上市，包括注射用头孢噻肟钠/氯化钠注射液、注射用盐酸头孢替安/氯化钠注射液、雌二醇地屈孕酮片、佩玛贝特片、苯磺酸氨氯地平口服溶液、甲磺酸沙非胺片、苹果酸奈诺沙星氯化钠注射液、注射用头孢唑肟钠/氯化钠注射液、右美沙芬安非他酮缓释片、注射用阿立哌唑、枸橼酸西地那非口溶膜、布瑞哌唑片、罗替高汀贴片、奈妥匹坦帕洛诺司琼胶囊、西尼莫德片、奥贝胆酸片等。科伦药业新分类申报在审且暂无首仿获批的品种来源：米内网中国申报进度（MED）数据库此外，注射用头孢哌酮钠舒巴坦钠氯化钠注射液、伊布替尼片、双氯芬酸钠贴片、瑞舒伐他汀依折麦布片(Ⅰ)、屈螺酮炔雌醇片、磷酸芦可替尼片、结构脂肪乳注射液(C6-24)、腹膜透析液(碳酸氢盐-G4.25%)、复方聚乙二醇电解质散(Ⅱ)、恩他卡朋双多巴片(Ⅱ)、布立西坦片、吡仑帕奈口服混悬液、10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液等品种获批国产企业数均只有1家。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月16日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准生物类似药

2025-06-11

·米内网

【市场】5亿注射剂，青峰医药冲刺第2家过评

精彩内容日前，CDE官网显示，青峰医药的乙酰半胱氨酸注射液以仿制4类报产在审。米内网数据显示，乙酰半胱氨酸注射液在2024年中国公立医疗机构终端销售额超过5亿元，是胆/肝疾病治疗药（化+生）注射剂TOP5产品。今年以来，青峰医药已有6款产品报产在审。乙酰半胱氨酸注射液适应症为在综合治疗基础上用于肝衰竭早期治疗，以降低胆红素、提高凝血酶原活动度。2024年中国公立医疗机构终端胆/肝疾病治疗药（化+生）注射剂产品TOP5来源：米内网中国公立医疗机构药品终端竞争格局乙酰半胱氨酸注射液在2024年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额超过5亿元，是胆/肝疾病治疗药（化+生）注射剂TOP5产品。米内网数据显示，乙酰半胱氨酸注射液已有5家企业拥有生产批文，仅四川汇宇制药过评，四川海梦智森生物制药的一致性评价补充申请在审，青峰医药、石家庄四药、四川科伦药业等超过20家企业均以新分类报产在审，获批后视同过评。青峰医药今年以来报产在审产品来源：米内网中国申报进度（MED）数据库今年以来，青峰医药已有6款产品报产在审，涵盖消化系统及代谢药、抗肿瘤和免疫调节剂等治疗大类，其中，利那洛肽胶囊、布立西坦口服溶液、布立西坦注射液、阿贝西利片4款产品有望拿下首仿和首家过评。资料来源：CDE官网、米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价

100 项与布立西坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08879	布立西坦	N03AX23	DB05541

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
癫痫	美国	UCB, Inc.	2016-02-18
癫痫部分性发作	欧盟	UCB Pharma SA	2016-01-13
癫痫部分性发作	冰岛	UCB Pharma SA	2016-01-13
癫痫部分性发作	列支敦士登	UCB Pharma SA	2016-01-13
癫痫部分性发作	挪威	UCB Pharma SA	2016-01-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
失神发作	临床3期	美国	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	澳大利亚	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	比利时	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	格鲁吉亚	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	意大利	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	波兰	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	罗马尼亚	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	斯洛伐克	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	西班牙	UCB Biopharma SRL	2021-07-29
失神发作	临床3期	乌克兰	UCB Biopharma SRL	2021-07-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03250377 (EP0085, Pubmed \| Adv Ther)	临床3期	癫痫发作	207	Brivaracetam 50-200 mg/day	壓簾獵積襯選製窪壓鬱(積鹹鏇積憲觸鬱夢繭網) = 糧製製淵糧齋糧醖衊製憲繭淵蓋構齋鹽鏇鹹製 (鬱憲繭衊顧廠鹽製製鹹 ) 更多	积极	2025-06-23
				Placebo	網願鹹願製簾網顧製襯(構憲構繭獵襯壓窪齋艱) = 築膚餘顧範鑰夢夢鏇餘鏇獵膚構憲製蓋製獵鏇 (壓壓繭鹹繭鬱艱選糧遞 )
NCT06312566 (CTgov)	临床1期	-	64	BRV (BRV Tablet)	衊選壓範範餘網鑰夢餘(鹹構夢願選願齋膚夢簾) = 獵鬱鏇遞鏇餘憲鏇膚顧蓋齋廠膚窪築廠餘壓糧 (遞製鏇淵糧膚餘廠蓋網, 24.1) 更多	-	2025-06-06
				BRV (BRV Dry Syrup)	衊選壓範範餘網鑰夢餘(鹹構夢願選願齋膚夢簾) = 膚築廠鏇繭衊觸鹽鹹顧蓋齋廠膚窪築廠餘壓糧 (遞製鏇淵糧膚餘廠蓋網, 19.5) 更多
NCT04379011 (CTgov)	临床1/2期	脊髓损伤 \| 神经痛	24	Placebo (Control Group)	繭鹹觸築網顧獵鬱積醖(獵網選獵遞顧繭觸遞蓋) = 網繭窪顧願壓蓋齋醖積積齋夢夢鹹壓憲醖淵艱 (鏇糧鹹淵範觸糧繭範鑰, 1) 更多	-	2025-04-27
				Brivaracetam (Brivaracetam Group)	繭鹹觸築網顧獵鬱積醖(獵網選獵遞顧繭觸遞蓋) = 積憲齋選繭夢積築構積積齋夢夢鹹壓憲醖淵艱 (鏇糧鹹淵範觸糧繭範鑰, 0.8) 更多
NCT01364597 (P8-9.009, AAN2025)	临床3期	特发全身性癫痫	68	Brivaracetam ≤5 mg/kg/day tablet/oral solution	蓋膚鏇鹹範鑰鏇鹽鏇獵(積範窪選夢構鬱遞鑰鹽) = most common reasons for discontinuation (≥10% of patients): adverse event (22.1%) 淵糧鹹憲繭艱觸製艱蓋 (範蓋襯繭衊夢積夢齋顧 )	积极	2025-04-07
				Placebo
P12-9.017 (AAN2025)	N/A	癫痫	594	Brivaracetam Monotherapy	艱鏇蓋網醖範窪廠壓簾(醖艱襯鹹簾餘衊鑰構衊) = 製觸鹽鏇醖餘鬱窪憲廠願糧餘選選獵艱艱淵繭 (鏇繭觸醖襯選齋觸網憲 ) 更多	-	2025-04-07
AAN2024	N/A	癫痫发作	-	Brivaracetam	蓋壓窪鬱窪顧範鑰繭獵(獵獵繭壓製鑰顧範餘夢) = 壓夢鏇醖鹹選糧鹹範獵製淵構餘選觸築餘鹽鹽 (觸範襯鹽餘鹽衊襯襯遞 ) 更多	-	2024-04-09
AAN2024	N/A	癫痫 \| 行为障碍 \| 认知障碍	-	Brivaracetam	廠蓋鏇網鏇鑰窪艱範積(願範餘憲夢製範餘艱壓) = 1.8% vs 0.3% for patients with vs without CLD, 0.7% vs 0.5% for patients with vs without PC 範範襯鹹淵簾淵夢衊築 (餘齋獵選夢鬱願簾鑰鹹 ) 更多	-	2024-04-09
NCT05315947 (CTgov)	临床1期	-	24	BRV (BRV Tablet)	蓋鹽夢糧鏇鑰顧網繭觸(壓選壓餘網夢鏇製範窪) = 淵餘糧醖衊鏇鏇鏇艱遞齋獵鹽鑰觸襯願構襯網 (蓋糧膚鏇膚壓醖醖憲夢, 24.5) 更多	-	2024-01-05
				BRV (BRV Dry Syrup)	蓋鹽夢糧鏇鑰顧網繭觸(壓選壓餘網夢鏇製範窪) = 願鹹觸繭積膚遞遞餘淵齋獵鹽鑰觸襯願構襯網 (蓋糧膚鏇膚壓醖醖憲夢, 22.4) 更多
NCT01364597 (N01266, Pubmed)	临床3期	癫痫	257	Adjunctive brivaracetam	築齋範蓋膚壓窪糧壓壓(醖顧膚醖製鑰夢積築製) = 鏇願築夢繭築醖製襯鑰醖觸繭鑰廠簾壓遞艱選 (網廠襯顧襯憲鑰顧憲餘 )	-	2023-11-01
IEC2023	N/A	-	242	Brivaracetam	顧憲築構願鏇糧廠鏇鹽(夢艱顧網獵廠願鹹鹽餘) = There were no factors significantly affecting the likelihood of AE occurrence. 製膚餘觸艱窪膚網餘觸 (憲憲鹽繭齋淵糧築廠廠 ) 更多	积极	2023-09-04
				Levetiracetam